Interpace Diagnostics Group (PF4) AI Stock Analysis

0 Followers

Interpace Diagnostics Group

(Munich:PF4)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Profitability TurnaroundThe shift from sizable earlier losses to sustained profitability through 2023–2025 indicates materially improved operating performance. If maintained, positive operating income can strengthen internal funding capacity, support investment in diagnostic offerings, and reduce reliance on external capital over the next several quarters.

Negative Factors

Revenue DeclineFalling revenue weakens the underlying growth profile of the diagnostics business and may limit operating leverage, reinvestment capacity, and future earnings expansion. Continued contraction could offset recent profitability gains by reducing test volume or the revenue base supporting fixed operating costs.

Interpace Diagnostics Group (PF4) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 36.59M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): 0.2
Beta (1Y): -0.21
Revenue Growth: -26.06%
EPS Growth: 480.57%
Country: Germany
Employees: 102
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Diagnostics & Research

Interpace Diagnostics Group Business Overview & Revenue Model

Company Description

Interpace Biosciences, Inc. is a U.S.-based company specializing in advanced molecular diagnostic tests, bioinformatics, and pathology services, primarily focused on assessing cancer risk. Among its key offerings is PancraGEN, a comprehensive genomic...

Interpace Diagnostics Group Risk Analysis

Interpace Diagnostics Group disclosed 63 risk factors in its most recent earnings report. Interpace Diagnostics Group reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Interpace Diagnostics Group Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:PF4 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VCYT	70Outperform	$1.94B	15.79	9.27%	―	17.50%	311.25%
CSTL	63Neutral	$1.06B	-44.17	-4.89%	―	9.78%	-81.20%
NEO	54Neutral	$2.19B	-68.19	-3.97%	―	11.08%	71.76%
MYGN	53Neutral	$543.88M	-4.19	-40.40%	―	-2.63%	68.56%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GH	44Neutral	$21.02B	-42.06	249.03%	―	41.69%	-14.59%

* Healthcare Sector Average

Performance Comparison

DE:PF4 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:PF4	Interpace Diagnostics Group Inc.	6.40	1.97	44.61%
MYGN	Myriad Genetics	5.72	-0.63	-9.92%
VCYT	Veracyte Inc	25.11	-14.76	-37.02%
NEO	NeoGenomics Inc.	16.83	6.82	68.13%
GH	Guardant Health	154.78	60.65	64.43%
CSTL	Castle Biosciences	33.99	-0.13	-0.38%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Interpace Diagnostics Group AI Stock Analysis